Infoblox Inc. (NYSE:BLOX), Yandex NV (NASDAQ:YNDX) and BioDelivery Sciences International Inc. (NASDAQ:BDSI) surged early in the day today, while Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), Repros Pharmaceuticals Inc. (NASDAQ:RPRX) and Chimerix Inc. (NASDAQ:CMRX) posted significant losses.
Infoblox Surges on Earnings Results
A decade ago, no one talked about tail risk hedge funds, which were a minuscule niche of the market. However, today many large investors, including pension funds and other institutions, have mandates that require the inclusion of tail risk protection. In a recent interview with ValueWalk, Kris Sidial of tail risk fund Ambrus Group, a Read More
Infoblox Inc. reached the middle of the day up +6.41%, getting a boost from its fourth quarter earnings results. The company exceeded expectations on EPS and revenues and issued improved first-quarter revenue guidance as well. The automated network controller has climbed +15.98% in the past 30 days.
Yandex NV climbed +5.81% early in the day this Friday. The Russian internet company rolled out a new update to its translation app this week, beating Google to the offline punch. YNDX has gained +4.08% since reporting Q2 results on July 29th.
BioDelivery Sciences International surged +5.38% today, rebounding from yesterday’s -6.72% loss. This week, company CEO Mark Sirgo bought 2,000 BDSI shares, valued at $30,080.00. Billionaire Julian Robertson has held a position in the biotech firm since the fourth quarter of 2013 and has made a pretty penny on his investment, with BDSI up +172.33% YTD.
Keryx Biopharmaceuticals Slips
The share price of Keryx Biopharmaceuticals slipped -6.25% by noon today. Despite today’s drop, the Seth Klarman pick is up +21.39% in 2014.
Repros Therapeutics dipped -5.25% midday. This week, Piper Jaffray downgraded its rating of the company to neutral. In the Farallon Capital portfolio since the first quarter of 2013, Repros is a clinical stage biopharmaceutical company. Its share price has gained +15.3% over the past month.
Chimerix Inc. reached midday with a -5.2% loss. The biopharmaceutical company said this week that one of its antiviral experimental drugs has showed progress against Ebola, but the news apparently hasn’t swayed investors significantly. That being said, Chimerix’s share price is up +51.03% YTD.